Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics
Severe asthma represents an important clinical unmet need despite the introduction of biologic agents. Although advanced omics technologies have aided researchers in identifying clinically relevant molecular pathways, there is a lack of an integrated omics approach in severe asthma particularly in t...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2023-04-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/9/2/00485-2022.full |
| _version_ | 1797809400582242304 |
|---|---|
| author | Ji-Hyang Lee Piers Dixey Pank Bhavsar Katie Raby Nazanin Kermani Marc Chadeau-Hyam Ian M. Adcock Woo-Jung Song Hyouk-Soo Kwon Sei-Won Lee You Sook Cho Kian Fan Chung Tae-Bum Kim |
| author_facet | Ji-Hyang Lee Piers Dixey Pank Bhavsar Katie Raby Nazanin Kermani Marc Chadeau-Hyam Ian M. Adcock Woo-Jung Song Hyouk-Soo Kwon Sei-Won Lee You Sook Cho Kian Fan Chung Tae-Bum Kim |
| author_sort | Ji-Hyang Lee |
| collection | DOAJ |
| description | Severe asthma represents an important clinical unmet need despite the introduction of biologic agents. Although advanced omics technologies have aided researchers in identifying clinically relevant molecular pathways, there is a lack of an integrated omics approach in severe asthma particularly in terms of its evolution over time. The collaborative Korea–UK research project Precision Medicine Intervention in Severe Asthma (PRISM) was launched in 2020 with the aim of identifying molecular phenotypes of severe asthma by analysing multi-omics data encompassing genomics, epigenomics, transcriptomics, proteomics, metagenomics and metabolomics. PRISM is a prospective, observational, multicentre study involving patients with severe asthma attending severe asthma clinics in Korea and the UK. Data including patient demographics, inflammatory phenotype, medication, lung function and control status of asthma will be collected along with biological samples (blood, sputum, urine, nasal epithelial cells and exhaled breath condensate) for omics analyses. Follow-up evaluations will be performed at baseline, 1 month, 4–6 months and 10–12 months to assess the stability of phenotype and treatment responses for those patients who have newly begun biologic therapy. Standalone and integrated omics data will be generated from the patient samples at each visit, paired with clinical information. By analysing these data, we will identify the molecular pathways that drive lung function, asthma control status, acute exacerbations and the requirement for daily oral corticosteroids, and that are involved in the therapeutic response to biological therapy. PRISM will establish a large multi-omics dataset of severe asthma to identify potential key pathophysiological pathways of severe asthma. |
| first_indexed | 2024-03-13T06:52:08Z |
| format | Article |
| id | doaj.art-dd6833ae406a4df7b97118b804facb11 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-03-13T06:52:08Z |
| publishDate | 2023-04-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-dd6833ae406a4df7b97118b804facb112023-06-07T13:31:08ZengEuropean Respiratory SocietyERJ Open Research2312-05412023-04-019210.1183/23120541.00485-202200485-2022Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologicsJi-Hyang Lee0Piers Dixey1Pank Bhavsar2Katie Raby3Nazanin Kermani4Marc Chadeau-Hyam5Ian M. Adcock6Woo-Jung Song7Hyouk-Soo Kwon8Sei-Won Lee9You Sook Cho10Kian Fan Chung11Tae-Bum Kim12 Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea National Heart and Lung Institute, London, UK National Heart and Lung Institute, London, UK National Heart and Lung Institute, London, UK National Heart and Lung Institute, London, UK School of Public Health, Imperial College London, London, UK National Heart and Lung Institute, London, UK Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea National Heart and Lung Institute, London, UK Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Severe asthma represents an important clinical unmet need despite the introduction of biologic agents. Although advanced omics technologies have aided researchers in identifying clinically relevant molecular pathways, there is a lack of an integrated omics approach in severe asthma particularly in terms of its evolution over time. The collaborative Korea–UK research project Precision Medicine Intervention in Severe Asthma (PRISM) was launched in 2020 with the aim of identifying molecular phenotypes of severe asthma by analysing multi-omics data encompassing genomics, epigenomics, transcriptomics, proteomics, metagenomics and metabolomics. PRISM is a prospective, observational, multicentre study involving patients with severe asthma attending severe asthma clinics in Korea and the UK. Data including patient demographics, inflammatory phenotype, medication, lung function and control status of asthma will be collected along with biological samples (blood, sputum, urine, nasal epithelial cells and exhaled breath condensate) for omics analyses. Follow-up evaluations will be performed at baseline, 1 month, 4–6 months and 10–12 months to assess the stability of phenotype and treatment responses for those patients who have newly begun biologic therapy. Standalone and integrated omics data will be generated from the patient samples at each visit, paired with clinical information. By analysing these data, we will identify the molecular pathways that drive lung function, asthma control status, acute exacerbations and the requirement for daily oral corticosteroids, and that are involved in the therapeutic response to biological therapy. PRISM will establish a large multi-omics dataset of severe asthma to identify potential key pathophysiological pathways of severe asthma.http://openres.ersjournals.com/content/9/2/00485-2022.full |
| spellingShingle | Ji-Hyang Lee Piers Dixey Pank Bhavsar Katie Raby Nazanin Kermani Marc Chadeau-Hyam Ian M. Adcock Woo-Jung Song Hyouk-Soo Kwon Sei-Won Lee You Sook Cho Kian Fan Chung Tae-Bum Kim Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics ERJ Open Research |
| title | Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics |
| title_full | Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics |
| title_fullStr | Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics |
| title_full_unstemmed | Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics |
| title_short | Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics |
| title_sort | precision medicine intervention in severe asthma prism study molecular phenotyping of patients with severe asthma and response to biologics |
| url | http://openres.ersjournals.com/content/9/2/00485-2022.full |
| work_keys_str_mv | AT jihyanglee precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT piersdixey precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT pankbhavsar precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT katieraby precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT nazaninkermani precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT marcchadeauhyam precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT ianmadcock precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT woojungsong precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT hyouksookwon precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT seiwonlee precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT yousookcho precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT kianfanchung precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics AT taebumkim precisionmedicineinterventioninsevereasthmaprismstudymolecularphenotypingofpatientswithsevereasthmaandresponsetobiologics |